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Tumour-induced angiogenesis
The progressive enlargement and metastatic dissemination of an incipient tumour mass has long been recognised to be critically dependent on it acquiring the capacity to induce formation of new blood vessels from the extant tissue microvasculature, a process defined as 'tumourinduced angiogenesis'. [1] [2] [3] The induction of an analogous angiogenic response is also fundamental to the aetiology of other general and ophthalmic pathologies, including fibrosis, rheumatoid arthritis, proliferative diabetic retinopathy, and age-related macular degeneration. [4] [5] [6] The important contribution of vascular endothelial growth factor (VEGF) to the initiation of angiogenesis in these conditions is now well established, with beneficial outcomes of VEGF-targeted therapy beginning to be achieved in certain conditions. 7, 8 In spite of these encouraging results, it remains apparent that further basic and translational research is required for antiangiogenic therapy to realise its full clinical potential for patients with cancer [9] [10] [11] and for neovascular-driven ophthalmic pathologies. 12, 13 This ongoing need stems from the fact the initiation, directionality, and maintenance of angiogenesis is dictated by the dynamic balance between a multitude of pro-and antiangiogenic stimuli. 1, 2, 14, 15 In view of the inherently complex and potentially redundant nature of this tissue-level (contextual) control network, it is unlikely that VEGF, or indeed any single stimulus, will afford a generally efficacious anti-angiogenic target.
We have identified and cloned migration-stimulating factor (MSF), a novel motogenic/angiogenic factor, which seems to have a significant role in driving tumour progression. Our initial results further indicate that the manifestation of MSF bioactivity (in terms of both target cell selection and specific response) is stringently modulated by a network of contextual controls, including the presence of other soluble factors and the physico-chemical nature of the extracellular matrix (ECM). In this brief review, we discuss MSF in terms of (1) its molecular characterisation and diverse functionality, (2) the influence of contextual parameters in defining both its expression and effects on potential target cells, and (3) its possible use as a novel target for clinical intervention.
MSF: molecular characterisation and diverse functionality
MSF is an oncofoetal protein initially shown to be constitutively expressed in vitro by foetal and cancer patient fibroblasts, but not by their healthy adult counterparts. 16, 17 Unexpectedly, MSF-expressing fibroblasts were obtained from both tumour-associated 18 and distant uninvolved sites in cancer patients, thereby indicating the systemic nature of this abnormality. 19 Subsequent ex vivo studies have indicated that both MSF message and protein are expressed by fibroblasts, keratinocytes, and vascular endothelial cells in foetal skin, but not by the majority of these cells in the healthy adult skin. 20 MSF is expressed by tumour and tumourassociated stromal cells in the majority of tumours examined to date, including common carcinomas, melanomas, and gliomas 20, 21 (unpublished observations). MSF is the first genetically truncated isoform of human fibronectin to be identified. 20 Approximately 20 'full-length' fibronectin isoforms had already been characterised when MSF was cloned. All of these consist of two peptide chains (250-280 kDa) covalently linked by disulphide bonds at their respective C termini. 22 The expression of MSF is controlled at the posttranscriptional level by a two-step mechanism. The primary MSF transcript is initially generated from the single-copy fibronectin gene by read through of the intron separating exons III-1a and III-1b, followed by intra-intronic cleavage to produce a 5.9-kb MSF pre-message. 23 The pre-message remains sequestered within the nucleus, where it is rapidly degraded as a consequence of an AU-rich instability element in its 3 0 -UTR. 20, 23, 24 In cells expressing the MSF protein, the intron-derived 3 0 -sequence of the pre-message is cleaved for a second time to produce a 2.1-kb mature MSF message. This has a significantly shorter (195 bp) intron-derived 3 0 -sequence containing a 30-bp in-frame coding sequence (immediately contiguous with exon III-1a), followed by a 165-bp 3 0 -UTR containing several in-frame stop codons and a polyadenylation signal. The mature message is rapidly exported to the cytoplasm for translation. MSF is consequently a 70-kDa protein identical to the N terminus of a full-length fibronectin monomer (up to and including the amino-acid sequence coded by exon III-1a), with the addition of an MSF-unique (intron-coded) 10 amino-acid C terminus ( Figure 1 ). Zhao et al 25 described a similarly foreshortened fibronectin message in Zebrafish embryos. Truncated fibronectin isoforms have also been detected in cDNA libraries from goldfish and rainbow trout, as well as from mouse and human liver, prostate, ovary, brain, and spleen. 26 Using a polyclonal anti-murine MSF, we have recently documented the expression of MSF protein in mouse tissues during foetal development (C. Carr, P. Felts et al, unpublished observations).
MSF is a potent motogen, stimulating the migration of epithelial cells (normal and tumour), as well as adultderived skin fibroblasts, vascular endothelial cells, and pericytes ( Figure 2 ). These cells show a bell-shaped dose response with half-maximal activity manifesting at 0.1-1.0 pg/ml, that is, femtomolar concentrations. MSF also stimulates the migration of non-epithelial tumour cells and displays other bioactivities relevant to tumour progression, such as the upregulation of hyaluronan (HA) synthesis, proteolysis, and induction of angiogenesis 20, 21, [27] [28] [29] (unpublished observations). The angiogenic activity of MSF has been demonstrated in both in vitro and in vivo models. For example, MSF induces endothelial activation in vitro, as manifested by the adoption of a sprouting cell phenotype ( Figure 3 ). It also induces angiogenesis in rats ( Figure 4 ) and pigs when implanted subcutaneously, and in the chick embryo assay ( Figure 5 ). In the latter, different quantities of MSF were incorporated within dried methyl cellulose gels (MCGs), which were then applied to the yolk-sac membrane. The induction of a subjacent radial array of blood vessels 24 h later was considered a positive angiogenic response. MSF elicited a significant (bellshaped) angiogenic response over a broad concentration range of 0.5-500 ng/MCG.
The IGD tripeptide motif (isoleucine-glycineaspartate) is a highly conserved feature of fibronectin type I modules to which no biological functionality was initially ascribed. 22 MSF contains four such IGD motifs ( Figure 1) . In vitro mutagenesis studies 20 have indicated that the stimulation of fibroblast migration by MSF is mediated by the two IGD motifs present in type I modules I-7 and I-9, whereas all four IGD motifs affect endothelial cell migration. Critically, small IGDcontaining synthetic peptides mimic all MSF bioactivities, including the stimulation of cell migration, endothelial cell activation, and angiogenesis ( Figures  3-5) 20,30 (unpublished observations). It is important to note that none of these bioactivities are manifested by any full-length fibronectin isoform, apparently as a consequence of steric hindrance. 31, 32 Houard et al 29 have identified a second motif (HEEGH) in MSF module I-8 that seems to mediate the motogenic response of a breast cancer cell line (MCF7) and is additionally required for manifestation of its proteinase activity. Our recent data indicate that the motogenic response of certain target cells may be mediated by both IGD and HEEGH, whereas other cells only respond to the IGD motif.
The role of contextual tissue-level parameters in the control of MSF expression and manifestation of its bioactivities
The programmed control of gene expression during development has long been recognised to be regulated by epigenetic mechanisms. In contrast to their genetic (eg, mutational) counterparts, epigenetic mechanisms are mediated by reversible, although heritable (persistent), changes in DNA and/or histone methylation. We have recently demonstrated that MSF expression may be switched on and off in such a reversible and persistent manner. For example, a transient (2 h) exposure to TGF-b1 of normal adult fibroblasts (non-producers of MSF protein) growing on a 'wounded' substratum in vitro (such as denatured type I collagen or fibrin) induces expression of the MSF protein. This 'activated' phenotype is persistent for the entire subsequent life span of the treated cells when cultured in the absence of TGF-b and irrespective of the nature of the substratum. However, MSF expression may be switched off again at any time by a second transient exposure to TGF-b1, this time when the cells are growing on a 'healthy' matrix of native type I collagen ( Figure 6 ). It is important to note that this 'on-off' switch is repeatable and strictly requires the concerted action of TGF-b1 and the appropriate matrix; that is, exposure to TGF-b1 of previously activated cells growing on a wounded matrix will not switch off MSF expression. Initial data consistent with the involvement of epigenetic mechanisms have been provided by observations that a transient exposure of normal adult fibroblasts to 5-azacytidine, a pharmacological agent inducing changes in gene expression by CpG island demethylation, results in a persistent switch on of the MSF expression; again, this induced expression may be switched off by a subsequent exposure of activated cells to TGF-b1 when grown on a native collagen substratum ( Figure 6 ). These matrixdependent effects of TGF-b on MSF expression are consistent with numerous previous observations, indicating that the precise effects of TGF-b on target cells is determined by the nature of the ECM and other contextual cues. [33] [34] [35] [36] The potential clinical relevance of these findings is highlighted by observations that constitutive MSF expression by foetal and cancer patient fibroblasts may The induction of angiogenesis and fibroblast migration by MSF in the rat. Collagenous graft matrices were soaked for 24 h in either PBS buffer (control graft) or PBS containing 10 ng/ml MSF (MSF graft). These were then implanted subcutaneously in rats. Skin biopsies containing the grafts were excised, fixed, and paraffin-embedded 28 days after implantation. Arrowheads mark the edge of the grafts. (a) Control implant. Blood vessels (stained with biotinylated Griffonia simplicifolia lectin) and fibroblasts were principally confined to the host tissue surrounding the implant. (b) MSF implant. Significantly more blood vessels and fibroblasts have infiltrated the graft matrix in response to MSF. also be persistently switched off by the exposure of cells growing on a native collagen substratum to TGF-b1. The ability of potentially deleterious MSF expression to be switched off by pharmacological intervention suggests that it may be possible to develop novel therapeutic strategies on the basis of the modulation of MSF expression in a clinically desirable manner.
The functional response of target cells to MSF (and its IGD synthetic peptide mimetic) is also modulated by contextual parameters. For example, the stimulation of fibroblast migration is manifested by cells adherent to a native, but not denatured, type I collagen substratum. 20, 30 Native collagen may accordingly be considered to provide a 'permissive' substratum, whereas denatured collagen is 'non-permissive'. The motogenic response of pericytes, but not that of endothelial cells, exhibits similar matrix dependence (Figure 7) . The stimulation of fibroblast migration by MSF is also abrogated by various soluble factors, including TGF-b and NGAL, an endogenous MSF inhibitor produced by normal 'resting' keratinocytes. 37, 38 Interestingly, a distinct MSF inhibitor is produced by the resting endothelial cells (Figure 8a ). Homogeneous monolayer cultures of such 'resting' or 'cobblestone' cells (mimicking the endothelium lining mature blood vessels in vivo) are produced by maintaining confluent endothelial cells in the absence of exogenous angiogenic factors on a 2D substratum, including the surface of a three-dimensional (3D) gel of native type I collagen fibres. 39, 40 A network of elongated cells displaying a 'sprouting' phenotype is rapidly induced by the addition of various angiogenic factors (such as FGF-2, MSF, and VEGF), thereby forming a mixed culture of both resting and sprouting cells. 39, 40 Remarkably, endothelial cells uniformly adopt a sprouting phenotype when embedded within a 3D gel of native type I collagen in the absence of exogenous angiogenic factors (Figure 3 ). These observations suggest that sprouting cells may produce an endogenous angiogenic factor(s). We confirmed that such homogeneous cultures do indeed produce bioactive MSF, but not a bioactive MSF inhibitor (Figure 8b ). It thus seems that the resting endothelial cells cultured on the surface of a collagen gel may be induced to adopt a sprouting cell phenotype simply by transferring them within the 3D matrix, an example of how cell behaviour may be profoundly influenced by the physical interface between the cell and its ECM.
MSF bioactivities can also be abrogated by functionneutralising anti-MSF antibodies. 20 Exposure of endothelial cells to such an antibody rapidly results in the apoptotic death of sprouting cells induced by VEGF (or other angiogenic factors), without affecting the viability of co-cultured resting cells ( Figure 9 ). It thus seems that, in addition to inducing angiogenesis, MSF expressed by sprouting endothelial cells also acts as a convergent (downstream) autocrine survival factor for these cells.
These features of MSF biology are summarised in Figure 10 in which it is noted that (1) MSF may be expressed by several cell types, including epithelial (normal and tumour), fibroblasts, and endothelial cells, (2) MSF is a pleiotropic effector, capable of eliciting multiple responses from various target cell types, and (3) the expression of MSF and its precise effect on target cells are modulated by a hierarchy of contextual control networks involving the inter-dependent signalling of soluble factors and the ECM. In this complex framework, MSF may function in both an autocrine and a paracrine manner. The inter-dependent modulatory effects of the ECM and soluble factors on both MSF expression and target cell response are consistent with the now wellrecognised dynamic and reciprocal contextual control of cell behaviour by multiple 'tissue-level' cues. 33, 34, 41, 42 An important corollary of this understanding is that the temporal and spatial expression of MSF by its various potential producer cells, as well as the precise response (or lack of it) by its potential target cells, is not invariant, but may change in response to alterations to the tissue microenvironment during disease progression.
MSF as a novel target for clinical intervention
MSF is present in more than 80% of common human tumours. Recent data indicate that high MSF expression by tumour and tumour-associated stromal cells is associated with poor survival in patients with breast cancer and oral cancer (unpublished observations). Such findings suggest that MSF is a novel tumour biomarker and assessment of its expression can provide independent prognostic information.
The diverse functionality of MSF is consistent with its postulated role as a driver of cancer progression. In this regard, we draw specific attention to (1) its capacity to stimulate the migration/invasion of host and tumour cells, (2) its effects on matrix remodelling, including stimulation of HA synthesis, (3) its induction of angiogenesis, and (4) its possible role as a specific survival factor for angiogenic endothelial cells. The latter finding raises the intriguing possibility of selectively inducing the destruction of tumour-induced angiogenic vessels while sparing mature host vessels. Independent evidence supporting a role for MSF in cancer pathogenesis has recently come from the study by Hu et al. 21 Using an unbiased proteomic screen, these authors identified MSF as a critical angiogenic factor driving oesophageal cancer progression. Yoshino et al 43 have additionally reported that exposure of a bronchioloalveolar carcinoma cell line to the tobacco carcinogen benzo[a]pyrene resulted in the induction of MSF expression.
Conversely, it should be noted that a failure to mount an appropriate angiogenic response contributes to the aetiology of common pathologies, such as chronic ulceration. In these situations, topical application of MSF or a synthetic agonist (such as IGDS) may help 'kick-start' the healing process. 44 This possibility is supported by a pilot study, indicating that application of MSF or IGDS significantly promotes wound closure and granulation tissue neovascularisation in diabetic mice (unpublished observations).
The various facets of MSF expression and bioactivity outlined above suggest that MSF may be considered as a novel target for clinical intervention. Such intervention strategies may involve agents that modulate its reversible expression (including siRNA therapy) and/or abrogating manifestation of its bioactivities (eg, by function-neutralising antibodies and/or pharmacological agents). The clear influence of microenvironmental parameters in modulating both its expression and manifestation of its bioactivities offer additional potential means of clinical manipulation.
